Biocon JV sets up in UAE

By Anna Lewcock

- Last updated on GMT

Related tags: Joint venture, United arab emirates

Indian biotech heavyweight Biocon has today announced that its
joint venture with Abu Dhabi-based Neopharma has spawned new
company NeoBiocon, operating out of one of Dubai's newest
biotechnology parks.

The two companies announced the 50:50 joint venture (JV) in January this year, and the new company has finally been established at DuBiotech, the Dubai Research and Biotechnology Park. The link-up between the companies looks to exploit Biocon's technological expertise along with Neopharma's manufacturing capabilities and local knowledge, to establish a company that will serve the United Arab Emirates (UAE). The joint venture represents Biocon's first foray into the Gulf Cooperation Council (GCC) market of six Arab states: UAE, Bahrain, Kuwait, Saudi Arabia, Oman and Qatar, and will see the introduction of a number of Biocon's products to these countries. According to Kiran Mazumdar-Shaw, managing director of Biocon, "[the company's] long term vision is to ensure that the country is self-sufficient in terms of biopharmaceutical products."​ The new company seeks to develop and market niche pharmaceutical products in key therapeutic areas such as oncology, diabetes, autoimmune disorders, obesity and cardiology. According to Biocon, biotherapeutics for cardiovascular, diabetes and oncology sectors represent the fastest growing class of drugs in the $5bn (€3.7bn) GCC pharmaceutical market. The location of the new company at DuBiotech will place it at a dedicated science and biotechnology industry park, which offers the benefits of being 100 per cent tax-free as well allowing 100 per cent foreign ownership and 100 per cent repatriation of profits abroad. Neopharma has already established itself as one of the region's top pharmaceutical manufacturers, and despite being only a few years old already ranks among the top 15 companies in the UAE. The deal with Biocon significantly strengthens Neopharma's therapeutic portfolio, and ups its profile in the market for biotech products. The company's two manufacturing plants have been designed so that production of betalactan products is kept separate from manufacture of other 'general' products. The site has been designed according to US Food and Drug Administration (FDA) guidelines, and has large-scale production capacity for tablets, capsules and liquid orals as well as blister packaging products. Having already gained good manufacturing practice (GMP) certification from the EU authorities as well as local approval from UAE and GCC, the company's facility is also being increasingly recognised as a regional contract manufacturing hub for international pharma companies, according to Neopharma. Although also planning excursions into European markets itself, Neopharm insists that the "domestic market will continue to be in the limelight."

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us

Products

View more

Webinars